Review
Nature Reviews Drug Discovery 5, 37-50 (January 2006) | doi:10.1038/nrd1930
There is an Erratum (1 February 2006) associated with this article.
Epigenetic therapy of cancer: past, present and future
Christine B. Yoo1 & Peter A. Jones1 About the authors
Abstract
The initiation and progression of cancer is controlled by both genetic and epigenetic events. Unlike genetic alterations, which are almost impossible to reverse, epigenetic aberrations are potentially reversible, allowing the malignant cell population to revert to a more normal state. With the advent of numerous drugs that target specific enzymes involved in the epigenetic regulation of gene expression, the utilization of epigenetic targets is emerging as an effective and valuable approach to chemotherapy as well as chemoprevention of cancer.
- View At a Glance
Author affiliations
- USC/Norris Comprehensive Cancer Center, Department of Urology, and Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, California 90089, USA.
Correspondence to: Peter A. Jones1 Email: jones_p@ccnt.hsc.usc.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Il2 transcription unleashed by active DNA demethylationNature Immunology News and Views (01 Mar 2003)
